V-ATPase-a2 inhibitor

V-ATPase-a2 inhibitors are a class of therapeutic agents that target the a2 isoform of the vacuolar-type H+-ATPase (V-ATPase), a multi-subunit proton pump responsible for maintaining pH gradients across biological membranes. In various cancers, particularly chemo-resistant ovarian cancer, the a2 isoform is overexpressed on the plasma membrane and within endosomal compartments, where it contributes to tumor survival and drug resistance. Inhibition of V-ATPase-a2 disrupts the autophagy flux, leading to the accumulation of autophagosomes (characterized by increased levels of LC3B and p62) and sensitizing resistant cancer cells to platinum-based therapies like cisplatin. Research conducted at the Rosalind Franklin University of Medicine and Science suggests that targeting this specific isoform can modulate the tumor microenvironment and overcome protective stress responses in malignant cells.

Other names

V-ATPase-a2 inhibitorsV-ATPase-a-2 inhibitorsV-ATPase-a 2 inhibitorsa2 isoform V-ATPase inhibitora-2 isoform V-ATPase inhibitora 2 isoform V-ATPase inhibitorATP6V0A2 inhibitorATP-6V0A2 inhibitorATP 6V0A2 inhibitorV-ATPase-a2v inhibitorV-ATPase-a-2v inhibitorV-ATPase-a 2v inhibitor